

# Gino Seravalle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8923034/publications.pdf>

Version: 2024-02-01

188  
papers

9,751  
citations

41344

49  
h-index

39675

94  
g-index

190  
all docs

190  
docs citations

190  
times ranked

8115  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sympathetic Activation in Obese Normotensive Subjects. <i>Hypertension</i> , 1995, 25, 560-563.	2.7	472
2	Baroreflex Control of Sympathetic Nerve Activity in Essential and Secondary Hypertension. <i>Hypertension</i> , 1998, 31, 68-72.	2.7	443
3	Obesity and hypertension. <i>Pharmacological Research</i> , 2017, 122, 1-7.	7.1	430
4	Sympathetic Activation in the Pathogenesis of Hypertension and Progression of Organ Damage. <i>Hypertension</i> , 1999, 34, 724-728.	2.7	428
5	Sympathetic Activation and Loss of Reflex Sympathetic Control in Mild Congestive Heart Failure. <i>Circulation</i> , 1995, 92, 3206-3211.	1.6	351
6	Mechanisms responsible for sympathetic activation by cigarette smoking in humans.. <i>Circulation</i> , 1994, 90, 248-253.	1.6	347
7	Body Weight Reduction, Sympathetic Nerve Traffic, and Arterial Baroreflex in Obese Normotensive Humans. <i>Circulation</i> , 1998, 97, 2037-2042.	1.6	321
8	Early Sympathetic Activation in the Initial Clinical Stages of Chronic Renal Failure. <i>Hypertension</i> , 2011, 57, 846-851.	2.7	268
9	Adrenergic and Reflex Abnormalities in Obesity-Related Hypertension. <i>Hypertension</i> , 2000, 36, 538-542.	2.7	259
10	Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. <i>Diabetologia</i> , 2005, 48, 1359-1365.	6.3	259
11	Heart rate as marker of sympathetic activity. <i>Journal of Hypertension</i> , 1998, 16, 1635-1639.	0.5	231
12	Dissociation Between Muscle and Skin Sympathetic Nerve Activity in Essential Hypertension, Obesity, and Congestive Heart Failure. <i>Hypertension</i> , 1998, 31, 64-67.	2.7	228
13	Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals. <i>Journal of Hypertension</i> , 2003, 21, 1761-1769.	0.5	202
14	Adrenergic, Metabolic, and Reflex Abnormalities in Reverse and Extreme Dipper Hypertensives. <i>Hypertension</i> , 2008, 52, 925-931.	2.7	178
15	Sympathetic regulation of vascular function in health and disease. <i>Frontiers in Physiology</i> , 2012, 3, 284.	2.8	174
16	Effects of Chronic ACE Inhibition on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure. <i>Circulation</i> , 1997, 96, 1173-1179.	1.6	173
17	Sympathetic and Baroreflex Cardiovascular Control in Hypertension-Related Left Ventricular Dysfunction. <i>Hypertension</i> , 2009, 53, 205-209.	2.7	157
18	Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. <i>European Journal of Heart Failure</i> , 2014, 16, 977-983.	7.1	152

#	ARTICLE	IF	CITATIONS
19	Physical training and baroreceptor control of sympathetic nerve activity in humans.. Hypertension, 1994, 23, 294-301.	2.7	151
20	Sympathetic activation in cardiovascular disease: evidence, clinical impact and therapeutic implications. European Journal of Clinical Investigation, 2015, 45, 1367-1375.	3.4	140
21	The "neuroadrenergic hypothesis"™ in hypertension: current evidence. Experimental Physiology, 2010, 95, 581-586.	2.0	135
22	Short- and Long-Term Neuroadrenergic Effects of Moderate Dietary Sodium Restriction in Essential Hypertension. Circulation, 2002, 106, 1957-1961.	1.6	126
23	Neurogenic Abnormalities in Masked Hypertension. Hypertension, 2007, 50, 537-542.	2.7	121
24	Excessive Sympathetic Activation in Heart Failure With Obesity and Metabolic Syndrome. Hypertension, 2007, 49, 535-541.	2.7	117
25	Comparison between Reproducibility and Sensitivity of Muscle Sympathetic Nerve Traffic and Plasma Noradrenaline in Man. Clinical Science, 1997, 92, 285-289.	4.3	114
26	Sympathetic nervous system. Current Opinion in Nephrology and Hypertension, 2012, 21, 46-51.	2.0	102
27	Structural and Functional Alterations of Subcutaneous Small Resistance Arteries in Severe Human Obesity. Obesity, 2010, 18, 92-98.	3.0	98
28	Effects of Hypertension and Obesity on the Sympathetic Activation of Heart Failure Patients. Hypertension, 2003, 42, 873-877.	2.7	95
29	Early alterations of the baroreceptor control of heart rate in patients with acute myocardial infarction.. Circulation, 1990, 81, 939-948.	1.6	94
30	Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. International Journal of Cardiology, 2014, 177, 1020-1025.	1.7	93
31	Diurnal blood pressure variation and sympathetic activity. Hypertension Research, 2010, 33, 381-385.	2.7	89
32	Sympathetic Neural Overdrive in the Obese and Overweight State. Hypertension, 2019, 74, 349-358.	2.7	87
33	Obesity and cardiovascular risk. Journal of Hypertension, 2018, 36, 1427-1440.	0.5	86
34	Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. Journal of Hypertension, 2000, 18, 587-593.	0.5	83
35	Impairment of Thermoregulatory Control of Skin Sympathetic Nerve Traffic in the Elderly. Circulation, 2003, 108, 729-735.	1.6	80
36	Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates. Hypertension, 2018, 72, 483-491.	2.7	79

#	ARTICLE	IF	CITATIONS
37	Diagnosis and management of patients with white-coat and masked hypertension. <i>Nature Reviews Cardiology</i> , 2011, 8, 686-693.	13.7	75
38	Sympathetic Nervous System, Hypertension, Obesity and Metabolic Syndrome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 175-179.	2.2	73
39	Heart Rate, Sympathetic Cardiovascular Influences, and The Metabolic Syndrome. <i>Progress in Cardiovascular Diseases</i> , 2009, 52, 31-37.	3.1	69
40	Blood Pressure Responses to Renal Denervation Precede and Are Independent of the Sympathetic and Baroreflex Effects. <i>Hypertension</i> , 2015, 65, 1209-1216.	2.7	65
41	Long-Term Sympathoinhibitory Effects of Surgically Induced Weight Loss in Severe Obese Patients. <i>Hypertension</i> , 2014, 64, 431-437.	2.7	62
42	Sympathetic nerve traffic and baroreflex function in optimal, normal, and high-normal blood pressure states. <i>Journal of Hypertension</i> , 2015, 33, 1411-1417.	0.5	61
43	Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 473-481.	2.6	58
44	Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe. <i>Journal of Hypertension</i> , 2013, 31, 2018-2024.	0.5	58
45	Participation of the Hypothalamus-Hypophysis Axis in the Sympathetic Activation of Human Obesity. <i>Hypertension</i> , 2001, 38, 1316-1320.	2.7	56
46	Reflex cardiovascular control in congestive heart failure. <i>American Journal of Cardiology</i> , 1992, 69, 17-23.	1.6	54
47	Short-Versus Long-Term Effects of Different Dihydropyridines on Sympathetic and Baroreflex Function in Hypertension. <i>Hypertension</i> , 2003, 41, 558-562.	2.7	54
48	Evaluation of microvascular structure in humans. <i>Journal of Hypertension</i> , 2014, 32, 2120-2129.	0.5	53
49	Baroreflex Impairment by Low Sodium Diet in Mild or Moderate Essential Hypertension. <i>Hypertension</i> , 1997, 29, 802-807.	2.7	51
50	Tolerability and treatment compliance with angiotensin II receptor antagonists. <i>American Journal of Hypertension</i> , 2003, 16, 1066-1073.	2.0	49
51	Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction. <i>Journal of Hypertension</i> , 2019, 37, 443-448.	0.5	47
52	Baroreflex Function in Hypertension: Consequences for Antihypertensive Therapy. <i>Progress in Cardiovascular Diseases</i> , 2006, 48, 407-415.	3.1	46
53	Sympathetic Nerve Traffic and Asymmetric Dimethylarginine in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2620-2627.	4.5	46
54	Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. <i>Clinical Science</i> , 2001, 101, 141-146.	4.3	45

#	ARTICLE	IF	CITATIONS
55	Sympathetic Nervous System, Sleep, and Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 74.	3.5	45
56	Sympathetic Mechanisms, Organ Damage, and Antihypertensive Treatment. <i>Current Hypertension Reports</i> , 2011, 13, 303-308.	3.5	44
57	Obesity and cardiovascular risk. <i>Journal of Hypertension</i> , 2018, 36, 1441-1455.	0.5	44
58	Long-term chronic baroreflex activation. <i>Journal of Hypertension</i> , 2015, 33, 1704-1708.	0.5	42
59	Reinforcement of the adrenergic overdrive in the metabolic syndrome complicated by obstructive sleep apnea. <i>Journal of Hypertension</i> , 2010, 28, 1313-1320.	0.5	41
60	Role of the Sympathetic Nervous System in Hypertension and Hypertension-Related Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014, 21, 89-105.	2.2	40
61	Sympathetic Nerve Traffic Responses to Surgical Removal of Pheochromocytoma. <i>Hypertension</i> , 1999, 34, 461-465.	2.7	38
62	Behaviour of the adrenergic cardiovascular drive in atrial fibrillation and cardiac arrhythmias. <i>Acta Physiologica Scandinavica</i> , 2003, 177, 399-404.	2.2	37
63	Physical Exercise in Essential Hypertension. <i>Chest</i> , 1992, 101, 312S-314S.	0.8	36
64	Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications. <i>Current Vascular Pharmacology</i> , 2009, 7, 137-145.	1.7	36
65	Sympathetic neural overdrive in congestive heart failure and its correlates. <i>Journal of Hypertension</i> , 2019, 37, 1746-1756.	0.5	34
66	Association Between the European Society of Cardiology/European Society of Hypertension Heart Rate Thresholds for Cardiovascular Risk and Neuroadrenergic Markers. <i>Hypertension</i> , 2020, 76, 577-582.	2.7	33
67	Effects of Chronic Clonidine Administration on Sympathetic Nerve Traffic and Baroreflex Function in Heart Failure. <i>Hypertension</i> , 2001, 38, 286-291.	2.7	31
68	Cardiopulmonary receptor reflexes in normotensive athletes with cardiac hypertrophy.. <i>Circulation</i> , 1990, 82, 1222-1229.	1.6	30
69	Impact of the metabolic syndrome on subcutaneous microcirculation in obese patients. <i>Journal of Hypertension</i> , 2010, 28, 1708-1714.	0.5	30
70	Cigarette Smoking and the Adrenergic Nervous System. <i>Clinical and Experimental Hypertension</i> , 1992, 14, 251-260.	0.3	29
71	Sympathetic Response to Ventricular Extrasystolic Beats in Hypertension and Heart Failure. <i>Hypertension</i> , 2002, 39, 886-891.	2.7	28
72	Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias. <i>Journal of Hypertension</i> , 2004, 22, 1747-1753.	0.5	28

#	ARTICLE	IF	CITATIONS
73	Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy. <i>Journal of Hypertension</i> , 2017, 35, 2532-2536.	0.5	28
74	Muscle and skin sympathetic nerve traffic during physician and nurse blood pressure measurement. <i>Journal of Hypertension</i> , 2013, 31, 1131-1135.	0.5	26
75	Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2020, 38, 1436-1442.	0.5	26
76	The Sympathetic Nervous System and New Nonpharmacologic Approaches to Treating Hypertension: A Focus on Renal Denervation. <i>Canadian Journal of Cardiology</i> , 2012, 28, 311-317.	1.7	25
77	Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2021, 39, 408-416.	0.5	25
78	Sympathomoderating influence of benazepril in essential hypertension. <i>Journal of Hypertension</i> , 1992, 10, 373-378.	0.5	24
79	Autonomic imbalance and metabolic syndrome: unravelling interactions, mechanisms and outcomes. <i>Journal of Hypertension</i> , 2006, 24, 47-49.	0.5	24
80	Behaviour of regional adrenergic outflow in mild-to-moderate renal failure. <i>Journal of Hypertension</i> , 2009, 27, 562-566.	0.5	24
81	Lercanidipine in the management of hypertension: An update. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2017, 8, 155.	0.4	24
82	Sympathoexcitatory responses to the acute blood pressure fall induced by central or peripheral antihypertensive drugs. <i>American Journal of Hypertension</i> , 2000, 13, 29-34.	2.0	23
83	Role of Ambulatory Blood Pressure Monitoring in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2013, 15, 232-237.	3.5	22
84	Regional differences in sympathetic activation in lean and obese normotensive individuals with obstructive sleep apnoea. <i>Journal of Hypertension</i> , 2014, 32, 383-388.	0.5	22
85	Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure. <i>Clinical Research in Cardiology</i> , 2016, 105, 838-846.	3.3	22
86	Age- and Sex-Specific Reference Values for Media/Lumen Ratio in Small Arteries and Relationship With Risk Factors. <i>Hypertension</i> , 2018, 71, 1193-1200.	2.7	22
87	Sympathetic Activation in Obesity. <i>Hypertension</i> , 2010, 56, 338-340.	2.7	21
88	Adding Home and/or Ambulatory Blood Pressure to Office Blood Pressure for Cardiovascular Risk Prediction. <i>Hypertension</i> , 2021, 77, 640-649.	2.7	21
89	Cardiopulmonary receptor and arterial baroreceptor reflexes after acute myocardial infarction. <i>American Journal of Cardiology</i> , 1992, 69, 873-878.	1.6	20
90	Baroreflex and non-baroreflex modulation of vagal cardiac control after myocardial infarction. <i>American Journal of Cardiology</i> , 1999, 84, 525-529.	1.6	20

#	ARTICLE	IF	CITATIONS
91	The importance of endothelial dysfunction in resistance artery remodelling and cardiovascular risk. <i>Cardiovascular Research</i> , 2019, 116, 429-437.	3.8	20
92	Sympathetic overdrive in the metabolic syndrome: meta-analysis of published studies. <i>Journal of Hypertension</i> , 2020, 38, 565-572.	0.5	20
93	Investigation of reflexes from volume and baroreceptors during converting-enzyme inhibition in humans. <i>American Heart Journal</i> , 1989, 117, 740-745.	2.7	19
94	Effects of Amlodipine on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure. <i>Hypertension</i> , 1999, 33, 671-675.	2.7	19
95	Reproducibility patterns of plasma norepinephrine and muscle sympathetic nerve traffic in human obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 469-475.	2.6	19
96	Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1446-1451.	3.4	19
97	Structural Alterations of the Retinal Microcirculation in the "Prehypertensive" High- Normal Blood Pressure State. <i>Current Pharmaceutical Design</i> , 2013, 19, 2375-2381.	1.9	19
98	Association between ADRA1A gene and the metabolic syndrome: candidate genes and functional counterpart in the PAMELA population. <i>Journal of Hypertension</i> , 2011, 29, 1121-1127.	0.5	18
99	Sympathetic nervous system and hypertension: New evidences. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2022, 238, 102954.	2.8	18
100	White-Coat Hypertension Without Organ Damage: Impact on Long-Term Mortality, New Hypertension, and New Organ Damage. <i>Hypertension</i> , 2022, 79, 1057-1066.	2.7	18
101	Sympathetic nerve traffic and blood pressure changes after bilateral renal denervation in resistant hypertension: a time-integrated analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1351-1356.	0.7	16
102	Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. <i>Journal of Hypertension</i> , 2017, 35, 1685-1690.	0.5	16
103	Sympathetic Overactivation in Patients With Essential Hypertension and Hepatic Iron Overload. <i>Hypertension</i> , 2020, 76, 1444-1450.	2.7	16
104	Autonomic Cardiovascular Alterations in Chronic Kidney Disease: Effects of Dialysis, Kidney Transplantation, and Renal Denervation. <i>Current Hypertension Reports</i> , 2021, 23, 10.	3.5	16
105	How to Assess Sympathetic Nervous System Activity in Clinical Practice. <i>Current Clinical Pharmacology</i> , 2013, 8, 182-188.	0.6	16
106	Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. <i>Clinical Science</i> , 2001, 101, 141.	4.3	15
107	Metabolic syndrome and cardiometabolic risk: An update. <i>Blood Pressure</i> , 2009, 18, 7-16.	1.5	15
108	Sleep Apnea and Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 23-31.	2.2	15

#	ARTICLE	IF	CITATIONS
109	Effects of ageing on the cardiopulmonary receptor reflex in normotensive humans. <i>Journal of Hypertension</i> , 1988, 6, S141-144.	0.5	14
110	Heart rate as a sympathetic marker during acute adrenergic challenge. <i>Journal of Hypertension</i> , 2008, 26, 70-75.	0.5	14
111	Within-visit BP variability, cardiovascular risk factors, and BP control in central and eastern Europe. <i>Journal of Hypertension</i> , 2015, 33, 2250-2256.	0.5	14
112	Baroreflex activation therapy systems: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2019, 16, 1025-1033.	2.8	14
113	Blood Pressure Lowering Effects of Rimonabant in Obesity-related Hypertension. <i>Journal of Neuroendocrinology</i> , 2008, 20, 63-68.	2.6	13
114	Sympathetic Nerve Traffic and Arterial Baroreflex Function in Apparent Drug-Resistant Hypertension. <i>Hypertension</i> , 2019, 74, 903-909.	2.7	13
115	Sympathetic Neural Mechanisms Underlying Attended and Unattended Blood Pressure Measurement. <i>Hypertension</i> , 2021, 78, 1126-1133.	2.7	13
116	Effect of detraining on the cardiopulmonary reflex in professional runners and hammer throwers. <i>American Journal of Cardiology</i> , 1992, 69, 677-680.	1.6	12
117	The Complex Relationship Between Serum Uric Acid, Endothelial Function and Small Vessel Remodeling in Humans. <i>Journal of Clinical Medicine</i> , 2020, 9, 2027.	2.4	12
118	Cardiovascular consequences of poor compliance to antihypertensive therapy. <i>Blood Pressure</i> , 2011, 20, 196-203.	1.5	11
119	Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1560-1567.	4.5	11
120	Heart rate as cardiovascular risk factor. <i>Postgraduate Medicine</i> , 2020, 132, 358-367.	2.0	11
121	Heart rate as a predictor of cardiovascular risk. <i>Minerva Medica</i> , 2021, 112, 130-143.	0.9	11
122	Left ventricular hypertrophy and the "cardiogenic reflex" in man. <i>Journal of Hypertension</i> , 1991, 9, S43-S50.	0.5	10
123	Protective effects of renin-angiotensin blockade beyond blood pressure control. <i>Journal of Human Hypertension</i> , 2009, 23, 570-577.	2.2	10
124	Novel Antihypertensive Therapies: Renal Sympathetic Nerve Ablation and Carotid Baroreceptor Stimulation. <i>Current Hypertension Reports</i> , 2012, 14, 567-572.	3.5	10
125	Alterations in sympathetic nerve traffic in genetic haemochromatosis before and after iron depletion therapy: a microneurographic study. <i>European Heart Journal</i> , 2016, 37, 988-995.	2.2	10
126	Decreased adrenergic tone in acromegaly: evidence from direct recording of muscle sympathetic nerve activity. <i>Clinical Endocrinology</i> , 2012, 77, 262-267.	2.4	9



#	ARTICLE	IF	CITATIONS
127	Differential effects of enalaprilâ€“felodipine versus enalaprilâ€“lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. Journal of the American Society of Hypertension, 2016, 10, 244-251.	2.3	9
128	Left Ventricular Hypertrophy and Sympathetic Activity. Advances in Experimental Medicine and Biology, 1997, 432, 173-179.	1.6	9
129	Blood pressure control in resistant hypertension: new therapeutic options. Expert Review of Cardiovascular Therapy, 2010, 8, 1579-1585.	1.5	8
130	Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation. Current Vascular Pharmacology, 2014, 12, 63-68.	1.7	8
131	Do Combined Electrocardiographic and Echocardiographic Markers of Left Ventricular Hypertrophy Improve Cardiovascular Risk Estimation?. Journal of Clinical Hypertension, 2016, 18, 846-854.	2.0	8
132	Neuroadrenergic activation in obstructive sleep apnoea syndrome: a new selected meta-analysis - revisited. Journal of Hypertension, 2022, 40, 15-23.	0.5	8
133	HYT-Hypertension in Turkey: A Cross-Sectional Survey on Blood Pressure Control with Calcium Channel Blockers Alone or Combined with Other Antihypertensive Drugs. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 165-172.	2.2	7
134	Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study. Advances in Therapy, 2016, 33, 2173-2187.	2.9	7
135	Baroreflex Activation Therapy in Congestive Heart Failure: Novel Findings and Future Insights. Current Hypertension Reports, 2016, 18, 60.	3.5	7
136	Clinical Relevance of the Sympatheticâ€“Vascular Interactions in Health and Disease. Biomedicines, 2021, 9, 1007.	3.2	7
137	Effects of longâ€“term lercanidipine or hydrochlorothiazide administration on hypertensionâ€“related vascular structural changes. Blood Pressure, 2006, 15, 268-274.	1.5	6
138	Multiple sampling improves norepinephrine reproducibility in essential hypertension: a comparison with the microneurographic technique. Journal of Hypertension, 2008, 26, 2185-2190.	0.5	6
139	Sympathetic and baroreflex abnormalities in the uncomplicated prediabetic state. Journal of Hypertension, 2018, 36, 1195-1200.	0.5	6
140	Neuroadrenergic activation in obstructive sleep apnea syndrome: a systematic review and meta-analysis. Journal of Hypertension, 2021, 39, 2281-2289.	0.5	6
141	Effects of Cigarette Smoking on Systemic Hemodynamics. , 2000, 130, 21-30.		5
142	Blood Pressure Control and Antihypertensive Treatment. Current Vascular Pharmacology, 2012, 10, 506-511.	1.7	5
143	Home and ambulatory blood pressure in resistant hypertension. EuroIntervention, 2013, 9, R35-R41.	3.2	5
144	Cardiac hypertrophy impairs cardiac receptor control of circulation in man. Journal of Hypertension, 1989, 7, S56-57.	0.5	4

#	ARTICLE	IF	CITATIONS
145	Benefit versus risk of calcium antagonists in hypertensive patients with concomitant risk factors. <i>Journal of Hypertension</i> , 1996, 14, S33-S34.	0.5	4
146	Failure of monolateral renal nerve ablation to exert sympathoinhibitory and blood pressure lowering effects in a patient with resistant hypertension: A case report. <i>International Journal of Cardiology</i> , 2013, 169, e120-e121.	1.7	4
147	Sympathomodulation in congestive heart failure: From drugs to devices. <i>International Journal of Cardiology</i> , 2020, 321, 118-125.	1.7	4
148	Relationships between sympathetic markers and heart rate thresholds for cardiovascular risk in chronic heart failure. <i>Clinical Research in Cardiology</i> , 2023, 112, 59-67.	3.3	4
149	Effects of dilevalol on forearm circulation in essential hypertension. <i>American Journal of Cardiology</i> , 1989, 63, 121-124.	1.6	3
150	Sympathoinhibitory effects of statins in chronic kidney disease. <i>Journal of Hypertension</i> , 2011, 29, 2064-2067.	0.5	3
151	Sympatho-Vagal Imbalance in Hypertension. , 2012, , 345-348.		3
152	Limited reliability of heart rate as a sympathetic marker in chronic kidney disease. <i>Journal of Hypertension</i> , 2021, 39, 1429-1434.	0.5	3
153	Short-and long-term reproducibility of techniques employed to assess sympathetic tone in humans. <i>Journal of Hypertension</i> , 1993, 11, S166-S167.	0.5	2
154	Differential patterns of regional neuroadrenergic cardiovascular drive in acromegalic disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 333-337.	1.9	2
155	Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 289-296.	2.2	2
156	The Sympathetic Nervous System in Hypertension. <i>Contemporary Endocrinology</i> , 2018, , 201-212.	0.1	2
157	Assessment of heart rate as a sympathetic biomarker™: strengths and pitfalls. <i>Journal of Hypertension</i> , 2020, 38, 1460-1461.	0.5	2
158	Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease. <i>Clinical Autonomic Research</i> , 2021, 31, 491-498.	2.5	2
159	Targeting persistent normal left ventricular geometry in the general population: a 25-year follow-up study. <i>Journal of Hypertension</i> , 2021, 39, 952-960.	0.5	2
160	Alterations of the Cardiopulmonary Reflex with Hypertension and Aging in Man. <i>Clinical and Experimental Hypertension</i> , 1989, 11, 199-210.	0.3	1
161	Effect of Oral Dilevalol on Forearm Circulation in Essential Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1992, 19, 367-370.	1.9	1
162	9C.07. <i>Journal of Hypertension</i> , 2015, 33, e124-e125.	0.5	1

#	ARTICLE	IF	CITATIONS
163	Carotid Baroreceptor Stimulation in Resistant Hypertension and Heart Failure. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 233-239.	2.2	1
164	Role of Sympathetic Nervous System in the Metabolic Syndrome and Sleep Apnea. , 2015, , 165-175.		1
165	Baroreceptor Stimulation. , 2018, , 1323-1327.		1
166	Pheochromocytoma as a Clinical Model of Peripheral Sympathetic Overdrive: Old and New Findings. Current Hypertension Reports, 2019, 21, 90.	3.5	1
167	Neurohormonal Interactions. , 2015, , 137-150.		1
168	Secondary Hypertension and Cardiovascular Risk: An Overview. Updates in Hypertension and Cardiovascular Protection, 2020, , 197-209.	0.1	1
169	Transient effects of carotid baroreflex stimulation via the neck chamber device on central venous pressure. Journal of Clinical Hypertension, 2021, , .	2.0	1
170	Response to Sympathetic Activity, Heart Failure, Obesity, and Metabolic Syndrome: Is There Any Role for Sleep Apnea?. Hypertension, 2007, 49, .	2.7	0
171	10.1 Sympathetic Responses to Ventricular Extrasystolic Beats in Obese Subjects without and with Sleep Apnoea. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 290-290.	2.2	0
172	Response to Possible Difference in the Sympathetic Activation on Extreme Dippers With or Without Exaggerated Morning Surge. Hypertension, 2009, 53, .	2.7	0
173	The new concept of total cardiovascular risk management. Italian Journal of Medicine, 2011, 5, 169-174.	0.3	0
174	The "Sympathetic" Kidney: Multiples Effects of Renal Sympathetic Nerve Ablation. Current Hypertension Reviews, 2012, 8, 250-255.	0.9	0
175	8B.02. Journal of Hypertension, 2015, 33, e107.	0.5	0
176	Effects of Renal Denervation on Sympathetic Nervous System Activity. Updates in Hypertension and Cardiovascular Protection, 2016, , 303-319.	0.1	0
177	[OP.4B.08] PROGNOSTIC RELEVANCE OF ELECTROCARDIOGRAPHIC TP-TE INTERVAL IN THE GENERAL AND IN THE HYPERTENSIVE POPULATION. Journal of Hypertension, 2016, 34, e46.	0.5	0
178	[OP.6B.06] EVALUATION OF RELATIONSHIP BETWEEN CARDIO-ANKLE VASCULAR INDEX AND 24H AMBULATORY BLOOD PRESSURE VARIABLES. Journal of Hypertension, 2016, 34, e70.	0.5	0
179	Neural Mechanisms. Updates in Hypertension and Cardiovascular Protection, 2019, , 71-86.	0.1	0
180	Sympathetic Activation in Hypertension and in Hypertension-Related Metabolic Disease. Current Hypertension Reviews, 2011, 7, 60-65.	0.9	0

#	ARTICLE	IF	CITATIONS
181	The "Sympathetic" Kidney: Multiples Effects of Renal Sympathetic Nerve Ablation. Current Hypertension Reviews, 2012, 8, 250-255.	0.9	0
182	The Role of Carotid Baroreceptor Stimulation. , 2013, , 137-144.		0
183	Neurogenic and Non-neurogenic Mechanisms of White-Coat Hypertension. , 2015, , 51-60.		0
184	Arterial Alterations in Hypertension. , 2015, , 285-297.		0
185	Neurogenic Hypertension. , 2018, , 381-382.		0
186	Treatment of Resistant Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 639-652.	0.1	0
187	The Role of the Brain in Neurogenic Prehypertension. Updates in Hypertension and Cardiovascular Protection, 2019, , 349-360.	0.1	0
188	Microvascular Alterations in Obesity. Updates in Hypertension and Cardiovascular Protection, 2020, , 137-147.	0.1	0